Real-World Effectiveness of Racotumomab as Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Advanced non-small cell lung cancer (NSCLC) presents limited treatment options and poor prognosis.
• Racotumomab, an anti-idiotype monoclonal antibody vaccine targeting tumor gangliosides, has demonstrated efficacy in prior clinical trials.
• This study investigates the real-world effectiveness of racotumomab as maintenance therapy post-first-line chemotherapy for advanced NSCLC.

Purpose of the Study:

• To evaluate the real-world effectiveness of racotumomab as maintenance therapy in advanced NSCLC.
• To assess overall survival (OS) and identify factors influencing treatment outcomes.
• To compare racotumomab's efficacy against historical controls.

Main Methods:

• A multi-center observational study included 162 advanced NSCLC patients receiving racotumomab (2012-2024).
• Effectiveness was analyzed in the intention-to-treat (ITT) cohort.
• Overall survival (OS) was estimated, with subgroup analyses based on clinical and demographic factors.

Main Results:

• Median OS was 14.9 months, with a 5-year survival rate of 20%.
• Stage III disease, better ECOG performance status, and age <65 years correlated with longer survival.
• Racotumomab showed a favorable hazard ratio (HR 0.44 vs. supportive care; HR 0.55 vs. docetaxel).

Conclusions:

• Real-world data suggest racotumomab is a promising maintenance therapy for advanced NSCLC, even with current immune checkpoint inhibitors.
• Further research is warranted to explore racotumomab in combination with modern immunotherapies.
• Validation of predictive biomarkers for clinical response is essential.